Circulating tumor DNA detection and analysis system for cancer diagnosis and monitoring. Enables early cancer detection through blood-based liquid biopsy technology with high sensitivity and specificity.
Manufactured by
Guangdong Guangzhou, China
Burning Rock Dx (NASDAQ: BNR) is a global precision oncology leader specializing in NGS-based diagnostics for both tissue and liquid biopsy. With internationally accredited labs (CLIA, CAP, ISO15189, ISO13485) and deep NGS expertise, the company offers a broad portfolio of in-house assays and integrated solutions across the oncology development cycle. Burning Rock supports pharmaceutical development and decentralized clinical implementation, partnering with biopharma and clinical labs to advance trials, biomarker research, and real-world diagnostics. Key milestones include two NMPA-approved IVD kits, four CE-marked assays, and Breakthrough Device Designations from both the FDA and NMPA for its multi-cancer early detection test. Burning Rock is committed to transforming cancer care through innovative, science-driven solutions. In addition to the CLIA / CAP laboratory in the United States, we have a CLIA / CAP / ISO 15189 / ISO13485 lab in Guangzhou, China, which also obtained the technical certification of “High-throughput sequencing laboratory” issued by the Guangdong Center for Clinical Laboratory. We have passed over 200 inter-laboratory quality evaluations organized by NCCL, PQCC, EMQN, CAP, and other authoritative organizations.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
NOROVA
China · 4 relevant products
guangzhou biotron technolongy co.,ltd
China · 5 relevant products
GeneCker Co., Ltd.
South Korea · 3 relevant products
Aliko Scientific SA
France · 3 relevant products
GENETRON HEALTH (BEIJING) CO., LTD
China · 4 relevant products
HealthTec Logix
Kuwait · 2 relevant products
Origin Biotechnology Co., Ltd.
Taiwan · 1 relevant product
Siemens Healthineers
United States · 1 relevant product
HEMEX AG
Switzerland · 1 relevant product
Guangzhou Wondfo Biotech Co., Ltd.
China · 1 relevant product
38 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →6 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 83 closest product alternatives
NOROVA · China
An independently developed platform for detecting circulating tumor DNA with high sensitivity and specificity compared to traditional detection methods. This liquid biopsy approach enables non-invasive, painless diagnosis through a single blood sample for comprehensive cancer patient support.
NOROVA · China
An independently developed liquid biopsy platform for detecting circulating tumor cells with high sensitivity and specificity. This non-invasive blood-based test provides comprehensive tumor-related information for malignant tumor diagnosis and treatment guidance.
guangzhou biotron technolongy co.,ltd · China
Advanced liquid biopsy system for non-invasive detection and analysis of circulating tumor markers, circulating tumor cells, and cell-free DNA from blood samples.
GeneCker Co., Ltd. · South Korea
Integrated platform for cancer diagnosis utilizing liquid biopsy techniques with CRISPR/Cas9 technology. Includes complete workflow from sample collection through DNA sequencing to result analysis.
Aliko Scientific SA · France
Advanced genetic testing platform for cancer diagnosis and personalized medicine applications. The system has been validated across thousands of real-world clinical scenarios for reliability and accuracy.
GENETRON HEALTH (BEIJING) CO., LTD · China
Multi-biomarker screening solution for early-stage cancer identification. Analyzes blood samples to detect cancer-associated molecular signatures. Facilitates timely clinical intervention and improved patient outcomes.
Aliko Scientific SA · France
Liquid biopsy platform designed to detect and analyze circulating tumor cells in patient samples. Enables non-invasive cancer monitoring and personalized medicine applications through advanced genetic testing.
HealthTec Logix · Kuwait
Integrated diagnostic platform combining genomic sequencing with molecular analysis for precision medicine applications. Enables personalized treatment planning and early disease detection.
Origin Biotechnology Co., Ltd. · Taiwan
A molecular detection technology platform designed for rapid and accurate genetic screening and diagnosis. The system focuses on identifying hereditary and genetic diseases with clinical applications in prenatal and pediatric care.
Siemens Healthineers · United States
Integrated platform for advanced biomarker analysis supporting early disease detection, risk stratification, and prognostic assessment across cardiometabolic, liver, cardiovascular, and brain health conditions.
HEMEX AG · Switzerland
Comprehensive cancer drug resistance diagnostic platform providing insights into treatment resistance mechanisms. Guides clinical decision-making for resistant cancer cases.
Guangzhou Wondfo Biotech Co., Ltd. · China
Molecular diagnostics platform for nucleic acid detection and amplification-based testing. Enables identification of pathogens and genetic markers for infectious disease and other molecular-based diagnoses.
71 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products